These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
200 related articles for article (PubMed ID: 38416633)
41. Prostacyclin Use Among Patients with Pulmonary Arterial Hypertension in the United States: A Retrospective Analysis of a Large Health Care Claims Database. Burger CD; Pruett JA; Lickert CA; Berger A; Murphy B; Drake W J Manag Care Spec Pharm; 2018 Mar; 24(3):291-302. PubMed ID: 29406840 [TBL] [Abstract][Full Text] [Related]
42. Effectiveness and safety of endothelin receptor antagonists, alone and in combination therapy, in the pulmonary arterial hypertension-connective tissue disease subtype: A systematic review and meta-analysis. Shivakumar S; Thynne TR; Mohammadi L; Burdeniuk C; Mangoni AA Int J Rheum Dis; 2020 Oct; 23(10):1276-1287. PubMed ID: 32691518 [TBL] [Abstract][Full Text] [Related]
43. An evidence-based approach to the management of pulmonary arterial hypertension. Archer SL; Michelakis ED Curr Opin Cardiol; 2006 Jul; 21(4):385-92. PubMed ID: 16755209 [TBL] [Abstract][Full Text] [Related]
44. Endothelin receptor antagonists for pulmonary arterial hypertension. Liu C; Chen J; Gao Y; Deng B; Liu K Cochrane Database Syst Rev; 2021 Mar; 3(3):CD004434. PubMed ID: 33765691 [TBL] [Abstract][Full Text] [Related]
45. Targeted Drugs for Treatment of Pulmonary Arterial Hypertension: Past, Present, and Future Perspectives. Zheng W; Wang Z; Jiang X; Zhao Q; Shen J J Med Chem; 2020 Dec; 63(24):15153-15186. PubMed ID: 33314936 [TBL] [Abstract][Full Text] [Related]
46. Comparative Effectiveness of Pharmacologic Interventions for Pulmonary Arterial Hypertension: A Systematic Review and Network Meta-Analysis. Jain S; Khera R; Girotra S; Badesch D; Wang Z; Murad MH; Blevins A; Schmidt GA; Singh S; Gerke AK Chest; 2017 Jan; 151(1):90-105. PubMed ID: 27615023 [TBL] [Abstract][Full Text] [Related]
47. Long-term efficacies of selective vasodilators in pulmonary arterial hypertension: a comprehensive comparison using a spontaneous reporting database. Suzuki K; Yagi T; Kawakami J Naunyn Schmiedebergs Arch Pharmacol; 2024 Jul; 397(7):4981-4992. PubMed ID: 38180559 [TBL] [Abstract][Full Text] [Related]
48. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. Galiè N; Humbert M; Vachiéry JL; Vizza CD; Kneussl M; Manes A; Sitbon O; Torbicki A; Delcroix M; Naeije R; Hoeper M; Chaouat A; Morand S; Besse B; Simonneau G; J Am Coll Cardiol; 2002 May; 39(9):1496-502. PubMed ID: 11985913 [TBL] [Abstract][Full Text] [Related]
49. An evaluation of nebulized prostacyclin in patients with primary and secondary pulmonary hypertension. Mikhail G; Gibbs J; Richardson M; Wright G; Khaghani A; Banner N; Yacoub M Eur Heart J; 1997 Sep; 18(9):1499-504. PubMed ID: 9458458 [TBL] [Abstract][Full Text] [Related]
51. Pulmonary arterial hypertension: new insights into the optimal role of current and emerging prostacyclin therapies. Waxman AB; Zamanian RT Am J Cardiol; 2013 Mar; 111(5 Suppl):1A-16A; quiz 17A-19A. PubMed ID: 23414683 [TBL] [Abstract][Full Text] [Related]
52. Pathways in pulmonary arterial hypertension: the future is here. Sitbon O; Morrell N Eur Respir Rev; 2012 Dec; 21(126):321-7. PubMed ID: 23204120 [TBL] [Abstract][Full Text] [Related]
53. Targeted Therapies in Patients with Pulmonary Arterial Hypertension Due to Congenital Heart Disease. Mares A; Mukherjee D; Lange RA; Nickel NP Curr Vasc Pharmacol; 2022; 20(4):341-360. PubMed ID: 36125818 [TBL] [Abstract][Full Text] [Related]
54. Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions. Denton CP; Humbert M; Rubin L; Black CM Ann Rheum Dis; 2006 Oct; 65(10):1336-40. PubMed ID: 16793845 [TBL] [Abstract][Full Text] [Related]